INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Inhibitor Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.11+0.00 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $19.06M
- P/E (TTM)
- –
- Dividend yield
- –
Inhibitor Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Market Cap | $19.12M | $166.30M |
| Enterprise Value | $18.65M | $88.19M |
Income (trailing twelve months)
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$3.37M | -$21.40M |
| Net Income | -$3.31M | -$22.46M |
| EBITDA | -$3.37M | -$16.91M |
| EPS (Diluted) | -$0.01 | -$0.83 |
Returns
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -145.6% | -40.9% |
| Return on Capital Employed (ROCE) | -729.1% | -38.1% |
Balance sheet
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $515.76K | $61.43M |
| Total Debt | $47.83K | $118.52M |
| Net Cash (Debt) | $467.93K | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$2.56M | $49.09M |
| Book Value Per Share | -$0.01 | $1.37 |
| Tangible Book Value | -$2.56M | $23.52M |
| Working Capital | $411.91K | $76.81M |
Financial position
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.36 | 3.34 |
| Quick Ratio | 2.95 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.22M | -$12.35M |
Efficiency
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.65M | -$703.34K |
| Employee Count | 2 | 74 |
Dividends and yields
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -17.3% | -23.3% |
Shares
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 173,792,000 | 58,127,000 |
| Shares Change (YoY) | 0.22% | 10.9% |
| Shares Change (QoQ) | 0.71% | 0.54% |
Scores
| Measure | Inhibitor Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -137.71 | -0.22 |
| Piotroski F-Score | 0 | 4 |
Calculated by StockData from Inhibitor Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.